

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM685054

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
INTERPACE BIOSCIENCES, INC.		11/01/2021	Corporation: DELAWARE
INTERPACE DIAGNOSTICS CORPORATION		11/01/2021	Corporation: DELAWARE
INTERPACE DIAGNOSTICS, LLC		11/01/2021	Limited Liability Company: DELAWARE
INTERPACE PHARMA SOLUTIONS, INC.		11/01/2021	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	BROADOAK FUND V, L.P.
<b>Street Address:</b>	4800 MONTGOMERY LANE, SUITE 230
<b>City:</b>	BETHESDA
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20814
<b>Entity Type:</b>	Limited Partnership: DELAWARE

## PROPERTY NUMBERS Total: 25

Property Type	Number	Word Mark
<b>Registration Number:</b>	5142307	BARREGEN
<b>Registration Number:</b>	5210362	BARREGEN ESOPHAGEAL CANCER RISK CLASSIFI
<b>Registration Number:</b>	4646544	INTERPACE DIAGNOSTICS
<b>Registration Number:</b>	5072603	INTERPACE DIAGNOSTICS
<b>Registration Number:</b>	6092660	INTERPACE BIOSCIENCES
<b>Registration Number:</b>	6092700	INTERPACE PHARMA SOLUTIONS
<b>Serial Number:</b>	90531881	INTERPACE BIOSCIENCES
<b>Registration Number:</b>	4882368	
<b>Registration Number:</b>	5067909	
<b>Registration Number:</b>	4071426	MIRINFORM
<b>Registration Number:</b>	4071427	MIRINFORM
<b>Registration Number:</b>	5318439	PANDNA
<b>Registration Number:</b>	4796668	PANCRAGEN
<b>Registration Number:</b>	4729240	POWER IN PERFORMANCE

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	5504939	RESPRIDX
Registration Number:	4729279	THYGENX
Registration Number:	4882519	THYRAMIR
Registration Number:	5651597	THYGENEXT
Serial Number:	90539740	WE OWN THE FUTURE
Registration Number:	6343361	COVIANT
Serial Number:	90086014	COVIANT DX
Serial Number:	90452747	
Registration Number:	6407358	MARKERS THAT MATTER
Registration Number:	3208314	PATHFINDERTG
Serial Number:	88532986	THYGRESSA

#### CORRESPONDENCE DATA

Fax Number: 4156932222

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 4156932000

Email: crhem@cooley.com

Correspondent Name: Cooley LLP

Address Line 1: 3 Embarcadero Center, 20th Floor

Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	344711-103
NAME OF SUBMITTER:	C. Rhem
SIGNATURE:	/CR/
DATE SIGNED:	11/02/2021

#### Total Attachments: 8

source=Interpace - IP Security Agreement#page1.tif

source=Interpace - IP Security Agreement#page2.tif

source=Interpace - IP Security Agreement#page3.tif

source=Interpace - IP Security Agreement#page4.tif

source=Interpace - IP Security Agreement#page5.tif

source=Interpace - IP Security Agreement#page6.tif

source=Interpace - IP Security Agreement#page7.tif

source=Interpace - IP Security Agreement#page8.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of November 1, 2021 by and between BROADOAK FUND V, L.P. ("Lender"), INTERPACE BIOSCIENCES, INC., a Delaware corporation ("Parent"), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation ("Diagnostics Corporation"), INTERPACE DIAGNOSTICS, LLC, a Delaware limited liability company ("Diagnostics") and INTERPACE PHARMA SOLUTIONS, INC., a Delaware corporation ("Pharma Solutions", and together with Parent, Diagnostics Corporation, and Diagnostics, each and together, jointly and severally, "Borrower").

### RECITALS

A. Lender has agreed to make certain advances of money and to extend certain financial accommodations to Borrower (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Lender and Borrower dated as of October 29, 2021 (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lender is willing to make the Loans to Borrower, but only upon the condition, among others, that Borrower shall grant to Lender a security interest in certain Copyrights, Trademarks, Patents, and mask works to secure the Obligations of Borrower under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Borrower has granted to Lender a security interest in all of Borrower's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Documents, each Borrower hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure the Obligations under the Loan Documents, each Borrower grants and pledges to Lender a security interest in all of such Borrower's right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Lender under the Loan Documents. The rights and remedies of Lender with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Lender, as a matter of law or equity. Each right, power and remedy of Lender provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Lender of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, of any or all other rights, powers or remedies.

Each Borrower hereby authorizes Lender to file and/or record, in the relevant office(s), including the United States Patent and Trademark Office and the United States Copyright Office, this Intellectual Property Security Agreement and any and all amendments and/or modifications hereto, including to the Exhibits attached hereto from time to time, and other documents, without the signature of such Borrower either in Lender's name or in the name of Lender as Lender and attorney-in-fact for such Borrower.


Sections 11 (Choice of Law and Venue; Jury Trial Waiver; Judicial Reference), 12.2 (Indemnification), 12.4 (Severability of Provisions), 12.6 (Amendments in Writing; Waiver; Integration), 12.7 (Counterparts), 12.10

(Attorney's Fees, Costs and Expenses) and 12.11(Electronic Execution of Documents) of the Loan Agreement are incorporated herein by this reference as though set forth in full.


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

BORROWERS:


INTERPACE BIOSCIENCES, INC.

By:   
Name: Thomas W. Burnell  
Title: President


INTERPACE DIAGNOSTICS CORPORATION

By:   
Name: Thomas W. Burnell  
Title: President

INTERPACE DIAGNOSTICS, LLC

By:   
Name: Thomas W. Burnell  
Title: President

INTERPACE PHARMA SOLUTIONS, INC.

By:   
Name: Thomas W. Burnell  
Title: President

LENDER:

BROADOAK FUND V, L.P.

Signature: William Snider  
Print Name: William Snider  
Title: Manager

**Exhibit A**

**Copyrights**

None.

**Exhibit B**

Patents

**Interpace Diagnostics, LLC:**

Country	Serial No.	Filing Date	Patent No.	Issue Date	Expiration Date
MICRO RNAs DIFFERENTIALLY EXPRESSED IN PANCREATIC DISEASE AND USES THEREOF					
US	60/826173	19-Sep-2006			
US (Abandoned)	11/857948	19-Sep-2007			
US (Abandoned)	15/917935	12-Mar-2018			
MIRNAS AS BIOMARKERS FOR DISTINGUISHING BENIGN FROM MALIGNANT THYROID NEOPLASMS					
US	61/414778	17-Nov-2010			
US	13/299226	17-Nov-2011	10150999	11-Dec-2018	17-Nov-2031
US	16/188769	13-Nov-2018	11118231	14-Sep-2021	17-Nov-2031
US	17/400660	12-Aug-2021			
METHODS AND COMPOSITIONS INVOLVING MIR-135B FOR DISTINGUISHING PANCREATIC CANCER FROM BENIGN PANCREATIC DISEASE					
US	61/534332	13-Sep-2011			
US	61/536486	19-Sep-2011			
US	13/615066	13-Sep-2012	9644241	09-May-2017	13-Sep-2032
US	15/491399	19-Apr-2017	10655184	19-May-2020	13-Sep-2032
US (Abandoned)	16/855469	22-Apr-2020			
MIRNAS AS DIAGNOSTIC BIOMARKERS TO DISTINGUISH BENIGN FROM MALIGNANT THYROID TUMORS					
US	61/552451	27-Oct-2011			
US	61/552762	28-Oct-2011			
US (Abandoned)	13/662450	27-Oct-2012			
US (Abandoned)	15/873067	17-Jan-2018			
DIAGNOSTIC MIRNAS FOR DIFFERENTIAL DIAGNOSIS OF INCIDENTAL PANCREATIC CYSTIC LESIONS					
US	61/709411	04-Oct-2012			
US	61/716396	19-Oct-2012			
US (Abandoned)	13/801737	13-Mar-2013			
US (Abandoned)	15/826909	30-Nov-2017			
US (Abandoned)	16/869405	07-May-2020			

**Interpace Diagnostics Corporation:**

Country	Serial No.	Filing Date	Patent No.	Issue Date	Expiration Date
<b>METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA</b>					
US	62/267619	15-Dec-2015			
US (Abandoned)	15/378370	14-Dec-2016			
<b>TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS</b>					
US	60/620926	22-Oct-2004			
US	60/631240	29-Nov-2004			
US	60/644568	19-Jan-2005			
US	60/679968	12-May-2005			
US	60/679969	12-May-2005			
US (Abandoned)	11/255978	24-Oct-2005			
US (Abandoned)	11/256150	24-Oct-2005			
US (Abandoned)	11/256152	24-Oct-2005			
US (Abandoned)	11/255980	24-Oct-2005			
US (Abandoned)	14/305727	16-Jun-2014			
US	15/912654	06-Mar-2018	11143657	12-Oct-2021	23-Jul-2036
US	17/498365	11-Oct-2021			
<b>METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA</b>					
US	61/565879	01-Dec-2011			
US	61/640527	30-Apr-2012			
US	61/661256	18-Jun-2012			
US	13/692727	03-Dec-2012	10255410	09-Apr-2019	23-Jan-2033
US	13/954247	30-Jul-2013	10131942	20-Nov-2018	19-Mar-2033
US (Abandoned)	16/166486	22-Oct-2018			
US	16/285604	26-Feb-2019			
<b>METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN</b>					
US	61/731725	30-Nov-2012			
US	61/824623	17-May-2013			
US	61/840963	28-Jun-2013			
US	14/092036	27-Nov-2013	9341628	17-May-2016	23-Mar-2034
US	15/147960	06-May-2016	10444239	15-Oct-2019	27-Nov-2033
US	16/558489	03-Sep-2019			
<b>METHODS OF IDENTIFYING AND TREATING AGGRESSIVE THYROID TUMORS</b>					
US	62/573370	17-Oct-2017			
US	16/162883	17-Oct-2018			



**Exhibit C**

**Trademarks**

**Interpace Diagnostics, LLC**

<b>Word Mark</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
BARREGEN	86525982	05-Feb-2015	5142307	14-Feb-2017
BARAGEN (Abandoned)	86390390	10-Sep-2014		
BARREGEN ESOPHAGEAL CANCER RISK CLASSIFIER	86910938	17-Feb-2016	5210362	23-May-2017
BARREMIR (Abandoned)	87623146	26-Sep-2017		
INTERPACE DIAGNOSTICS (Abandoned)	86126455	22-Nov-2013		
INTERPACEDX (Abandoned)	86526999	06-Feb-2015		
INTERPACE DIAGNOSTICS	86130866	27-Nov-2013	4646544	25-Nov-2014
INTERPACE DIAGNOSTICS	86944287	17-Mar-2016	5072603	01-Nov-2016
INTERPACE BIOSCIENCES	88651133	11-Oct-2019	6092660	30-Jun-2020
INTERPACE PHARMA SOLUTIONS	88680696	05-Nov-2019	6092700	30-Jun-2020
INTERPACE BIOSCIENCES	90531881	17-Feb-2021		
[DESIGN ONLY]	86290079	23-May-2014	4882368	05-Jan-2016
[DESIGN ONLY]	86944266	17-Mar-2016	5067909	25-Oct-2016
MIRINFORM (Cancelled)	77447187	14-Apr-2008	3546361	16-Dec-2008
MIRINFORM	85067844	21-Jun-2010	4071426	13-Dec-2011
MIRINFORM	85067850	21-Jun-2010	4071427	13-Dec-2011
MANAGEMDX (Abandoned)	86434107	24-Oct-2014		
PANDNA	87178397	21-Sep-2016	5318439	24-Oct-2017
PANCRAGEN	86370325	19-Aug-2014	4796668	18-Aug-2015
PANCRAMIR (Abandoned)	86357914	05-Aug-2014		
POWER IN PERFORMANCE	86325980	01-Jul-2014	4729240	28-Apr-2015
RESPRIDX	87647404	16-Oct-2017	5504939	26-Jun-2018
THYMIRA (Abandoned)	86370332	19-Aug-2014		
THYGENX	86365003	13-Aug-2014	4729279	28-Apr-2015
THYRAMIR	86370328	19-Aug-2014	4882519	05-Jan-2016
THYGENEXT	87868479	09-Apr-2018	5651597	08-Jan-2019
WE OWN THE FUTURE	90539740	22-Feb-2021		

**Interpace Diagnostics Corporation**

<b>Word Mark</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
COVARIANT	88906872	08-May-2020	6343361	04-May-2021
COVARIANT DX	90086014	31-Jul-2020		
[DESIGN ONLY]	90452747	07-Jan-2021		

[Signature Page to Intellectual Property Security Agreement]

**TRADEMARK**  
**REEL: 007479 FRAME: 0971**

MARKERS THAT MATTER	90097773	06-Aug-2020	6407358	06-Jul-2021
PATHFINDERTG	78848127	28-Mar-2006	3208314	13-Feb-2007
SERACOV (Abandoned)	88906794	08-May-2020		
THYGRESSA	88532986	24-Jul-2019		

**Interpace Biosciences, Inc.**

<b>Word Mark</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Registration No.</b>	<b>Registration Date</b>
THYGRESSA	88532986	24-Jul-2019		